BIIB vs MRNA: stock comparison and AI forecast
Biogen Inc. (BIIB) and Moderna, Inc. (MRNA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BIIB Biogen Inc.
- Price
- $248.35 +29.8% · 6M
- Market Cap
- $36.71B
- P/E Ratio
- 107.1x
- Size
- large-cap
- AI Forecast
MRNA Moderna, Inc.
- Price
- $254.19 +423.7% · 6M
- Market Cap
- $101.48B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- MRNA is 2.8 times larger than BIIB by market capitalization ($101.48B against $36.71B).
- Over the last six months MRNA returned +423.7% and BIIB +29.8%.
- BIIB turns 3.4% of its revenue into net income, against -124.5% for MRNA.
- MRNA carries 0.97 times debt per unit of equity, against 0.69 times for BIIB.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BIIB | MRNA |
|---|---|---|
| Market Cap | $36.71B | $101.48B |
| P/E Ratio | 107.05x | – |
| P/B Ratio | 1.94x | 14.84x |
| EPS | $2.32 | $-7.08 |
| Book Value/Share | $128.01 | $17.13 |
| Revenue/Share | $69.66 | $5.61 |
| FCF/Share | $14.01 | $-4.93 |
Profitability & Margins
| Metric | BIIB | MRNA |
|---|---|---|
| ROE | 1.8% | -40.8% |
| ROA | 1.1% | -20.7% |
| ROIC | – | -25.6% |
| Gross Margin | 74.0% | 18.9% |
| Operating Margin | – | -130.8% |
| Net Margin | 3.4% | -124.5% |
| EBT Margin | 4.3% | -121.8% |
| Tax Rate | 21.9% | -2.2% |
Financial Health
| Metric | BIIB | MRNA |
|---|---|---|
| Current Ratio | 1.95x | 3.62x |
| Quick Ratio | 1.37x | 3.47x |
| D/E Ratio | 0.69x | 0.97x |
| Financial Leverage | 1.69x | 1.97x |
| Interest Coverage | 9.2x | -85.7x |
| Working Capital | $3.69B | $5.32B |
Cash Flow
| Metric | BIIB | MRNA |
|---|---|---|
| Operating Cash Flow | $2.25B | -$1.78B |
| Free Cash Flow | $2.07B | -$1.97B |
| Capital Spending | -$176M | -$185M |
| OCF Growth YoY | -8.4% | – |
| FCF Growth YoY | -10.1% | – |
| FCF/Sales | 20.1% | -87.9% |
| CapEx/Sales | 1.7% | 8.3% |
Operational Efficiency
| Metric | BIIB | MRNA |
|---|---|---|
| Asset Turnover | 0.32x | 0.17x |
| Receivables Turnover | – | 1.6x |
| Inventory Turnover | 1.2x | 5.8x |
| Fixed Assets Turnover | 3.5x | 1.1x |
| Days Sales Outstanding | – | 223 days |
| Days Inventory | 303 days | 63 days |
| Payables Period | 59 days | 52 days |
| Cash Conversion Cycle | – | 233 days |
Income Statement
| Metric | BIIB | MRNA |
|---|---|---|
| Total Revenue | $10.30B | $2.24B |
| Operating Income | – | -$2.93B |
| Net Income | $348M | -$2.79B |
| R&D Expense | $2.15B | $2.66B |
| SG&A Expense | $2.75B | – |
| Cost of Goods Sold | $2.68B | $1.82B |
Dividend & Shareholder Information
| Metric | BIIB | MRNA |
|---|---|---|
| Shares Outstanding | 148M | 399M |
| Net Income Growth | -78.4% | – |
| EPS Growth | -78.8% | – |
BIIB vs MRNA: stock comparison and AI forecast
Which is bigger, BIIB or MRNA?
MRNA is 2.8 times larger than BIIB by market capitalization ($101.48B against $36.71B).
Which stock performed better over the last six months, BIIB or MRNA?
Over the last six months MRNA returned +423.7% and BIIB +29.8%.
Which one does Intratio's AI model rank higher, BIIB or MRNA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.